Adverum biotechnologies, inc. (ADVM)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-18,925

-16,118

-14,954

-14,489

-15,659

-20,958

-18,810

-17,200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-16,099

-22,394

-14,301

-61,660

-15,392

-14,094

-14,084

-9,766

-9,509

-10,391

-8,256

-5,094

-1,663

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

354

373

420

426

389

262

640

459

504

536

540

516

487

453

343

320

306

241

147

118

79

49

25

9

Stock-based compensation expense

2,850

2,661

2,626

1,762

1,182

2,995

5,826

3,429

1,884

2,700

2,243

1,896

1,564

2,949

2,819

4,084

4,421

5,752

559

773

4,125

3,056

1,271

115

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

14

Amortization of premium and discounts on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-210

-253

-258

-59

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

289

433

37

Amortization of premium and accrued interest on marketable securities

-

-399

-285

-129

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use asset

-

542

539

539

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

10

-8

2

-40

2

-6

204

-183

50

167

-138

-89

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

-

-

-

-

-

-

-

-

0

0

0

-886

-

-

-

-

-

-

-

-

-

-

-

225

Receivable from collaborative partner

-

-

-

-

-

-

-

-

-

-

-

-

-

-48

-88

668

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

4,086

2,457

-680

91

-725

1,405

931

-818

355

712

-1,038

462

-1,388

2,386

-628

-441

-11

495

-73

120

-79

618

-65

150

Other asset

-

-

0

18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-

-

-

-

Accounts payable

30

244

-788

-136

-72

-389

1,440

-1,046

167

500

-1,944

1,610

-928

171

786

-140

-595

-251

-1,237

1,771

-133

13

-64

178

Accrued expenses and other current liabilities

18

3,920

334

-2,363

-138

-969

1,215

107

695

1,083

-1,520

229

-144

1,660

-1,030

-676

336

329

823

-764

1,317

594

724

269

Restructuring liabilities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-24

-964

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-493

292

-

-463

-463

-462

424

1,361

722

853

-954

-953

-203

-203

-

-

-

-

Deferred rent

-

-

-

-

-1,010

-292

33

26

27

27

23

20

18

20

16

11

11

12

-96

-134

-112

-48

-69

-69

Lease liability

4,824

1,678

-158

1,242

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-14,835

-9,530

-11,588

-13,217

-12,730

-16,900

-11,350

-12,984

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-11,817

-8,342

-9,647

-8,224

-12,153

-9,126

-9,220

-9,250

-7,742

-5,055

-4,973

5,727

-1,347

Purchases of marketable securities

-

-

48,095

22,454

-

-

15,762

30,374

8,749

28,250

34,197

138,591

-

-

-

-

0

-2

59

88,370

-

-

-

-

Maturities of marketable securities

53,362

53,770

14,000

27,385

30,986

31,196

30,824

55,973

-

-

-

-

0

0

0

37,738

-

-

-

-

-

-

-

-

Purchases of property and equipment

8,373

6,191

2,497

2,186

157

270

166

216

98

186

469

263

924

362

1,004

122

188

1,319

1,074

411

364

105

427

47

Net cash provided by (used in) provided by investing activities

-19,210

-15,016

-36,592

2,745

8,027

21,138

14,896

25,383

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-138,854

-924

-362

2,445

37,616

30,062

9,323

7,827

-88,781

-364

-105

-427

-47

Proceeds from offering of common stock, net of issuance costs

-

-

-

-

-

-

-

70,191

-

-

-

-

-

-

-

-

0

0

0

138,954

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,000

1,000

Proceeds from issuance of common stock pursuant to option exercises

824

144

2,312

162

1

115

264

308

55

-30

155

187

130

284

87

262

7

50

110

21

-

-

-

-

Taxes paid related to net share settlement of restricted stock units

59

207

700

504

154

101

135

801

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of BPI loan

28

28

28

28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from a financing arrangement

-

-

-

-

0

0

0

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

26,771

-91

1,881

-370

-21

-15

187

69,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents and restricted cash

-7,274

-24,637

-46,299

-10,842

-4,724

4,223

3,733

82,197

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

187

203

4

87

262

-275

50

110

138,975

-505

117,990

46,957

1,000

Effect of foreign currency exchange rate on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-117

-38

-26

-88

9

11

-14

1

-7

-1

-11

2

-1

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-150,601

-9,101

-10,031

-5,780

25,734

20,672

139

-1,312

42,445

-5,925

112,901

52,259

-395

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

Supplemental schedule of noncash investing information
Fixed assets in accounts payable and current liabilities

1,617

3,334

-122

413

1,338

240

-115

153

-33

24

-289

413

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued in connection with license agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

41

Fixed assets in accounts payable and current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

278

-

-

-

-

Deferred stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-141

-375

849

46

Fixed assets in accounts payable, accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

618

-423

576

-

-

-

-

-

-

-

-